Clinical Trial Update: Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial tested lenalidomide as maintenance therapy after Bendamustine and Rituximab induction in chronic lymphocytic leukemia; the study was terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Yale University | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2014-10-23